Short answer
Sight Sciences, Inc. (SGHT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $25M (up 25.2% year over year) with net income of −$7M.
Q3 2026 key financials · XBRL
- Revenue
- $25M
- +25.2% YoY · +6.6% QoQ
- Net income
- −$7M
- +16.6% YoY · −53.2% QoQ
- Operating margin
- -24.6%
- Gross margin
- 85.9%
- EPS (diluted)
- −$0.12
- +20.0% YoY · −50.0% QoQ
Source: XBRL data from the Sight Sciences, Inc. (SGHT) Q3 2026 10-Q on SEC EDGAR. USD.
Sight Sciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $24.9M, up 25.2% YoY from $19.9M
- Interventional Dry Eye strongest growth: $3.9M revenue vs $0.2M, gross margin 79.0% vs 37.8%
- Interventional Glaucoma largest segment: $21.0M revenue, up 6.7% YoY
- Total gross margin 85.9% vs 86.4% YoY, operating loss $6.1M vs $7.9M
- Cash $77.4M; operating cash use $15.1M vs $27.9M, management expects liquidity beyond 12 months
Risk Factors
- No material changes to risk factors since the Annual Report
- Business, results, liquidity, and prospects vulnerable to identified or currently unknown risks
- Common-stock trading price could decline, potentially causing total or partial investment loss
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sight Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.